- 23andMe Holding Co. is gearing up to capitalize on its growing genetic database by investing in new business verticals and industry-first services.
- The company engages in dialogue with the FDA and watch groups to ensure that its personalized services do not violate current or future genetic privacy regulations.
- With several series of funding and an independent board of well-connected directors, 23andMe has an abundance of social and financial capital to actualize its full growth potential.
For further details see:
23andMe: A Genetics Innovator Positioned For Growth